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Abstract
Background: A major handicap in developing a malaria vaccine is the difficulty in pinpointing the
immune responses that protect against malaria. The protective efficacy of natural or vaccine-
induced immune responses against malaria is normally assessed by relating the level of the
responses in an individual at the beginning of a follow-up period and the individual's experience of
malaria infection or disease during the follow-up. This approach has identified a number of
important responses against malaria, but their protective efficacies vary considerably between
studies.
Hypothesis: It is likely that apart from differences in study methodologies, differences in exposure
among study subjects within each study and brevity of antibody responses to malaria antigen are
important sources of the variation in protective efficacy of anti-malaria immune responses
mentioned above. Since malaria immunity is not complete, anyone in an area of stable malaria
transmission who does not become asymptomatically or symptomatically infected during follow-up
subsequent to treatment is most likely unexposed rather than immune.
Testing the hypothesis: It is proposed that individuals involved in a longitudinal study of malaria
immunity should be treated for malaria prior to the start of the study and only those who present
with at least an asymptomatic infection during the follow-up should be included in the analysis. In
addition, it is proposed that more closely repeated serological survey should be carried out during
follow-up in order to get a better picture of an individual's serological status.
Implications of the hypothesis: Failure to distinguish between individuals who do not get a
clinical episode during follow-up because they were unexposed and those who are genuinely
immune undermines our ability to assign a protective role to immune responses against malaria.
The brevity of antibodies responses makes it difficult to assign the true serological status of an
individual at any given time, i.e. those positive at a survey may be negative by the time they
encounter the next infection.
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Background
A major handicap in developing a malaria vaccine is the
difficulty in pinpointing the responses involved in immu-
nity to malaria and their target antigens [1-3]. The classic
approach for assessing the efficacy of natural or vaccine-
induced immune responses in protection against malaria
is to relate an individual's level of these responses at the
beginning of a follow-up period and experience of
malaria infection or disease during the follow-up. Using
this approach responses against a number of malaria anti-
gens have been shown to be associated with protection
against malaria but the strength of these association vary
considerably between studies [4-9]. These variations may,
in part, be due to differences in methodology, polymor-
phism of target antigens or epitopes and other factors,
such as variation in transmission and exposure [10].
In addition, some of the assumptions inherent in this
approach have implications for the interpretation of
results of such longitudinal studies. The first assumption
is that immune responses observed in an individual at the
time of a baseline survey persist throughout the follow-up
period (i.e. they provide a stable measure of immune
competence) and the second is that we can accurately dis-
tinguish "immune" from "susceptible" individuals based
on their disease experience during a given period. The dis-
cussion below illustrates why these assumptions may be
flawed.
Brevity of antibody responses to malaria 
antigens
Among people living in endemic areas, levels of antibod-
ies to many malaria antigens may vary with the seasonal-
ity of malaria transmission, often being higher during
periods of high malaria transmission than at the end of a
low transmission season [11-15]. Second, levels of anti-
bodies to malaria antigens often tend to be higher in indi-
viduals who also have malaria parasites at the time when
their antibodies are measured than in those without para-
sites [16-18] (Figure 1). These phenomena are typically
seen in young children, probably because adults typically
have much higher antibody levels that take longer to
decay appreciably even in the absence of an infection
[12,19,20]. These observations and those from other lon-
gitudinal studies [12,21,22], where malaria antibodies fell
from relatively high levels to low levels within a few weeks
of treatment of a clinical episode, suggest that antibody
responses to many malaria antigens are short-lived.
Recent studies at Kilifi, Kenya confirmed the brevity of
responses to several malaria merozoite antigens (MSP1,
MSP2, EBA-175 and AMA-1) by closely monitoring levels
Age-corrected odds ratios of children having low (L), medium (M) or high (H) levels of antibodies to VSA of various malaria  parasite isolates if the children were parasite positive at the time their serum was assayed compared to those who were not Figure 1
Age-corrected odds ratios of children having low (L), medium (M) or high (H) levels of antibodies to VSA of 
various malaria parasite isolates if the children were parasite positive at the time their serum was assayed 
compared to those who were not. The odd ratios of having medium or high levels were significantly greater than 1 in all 
case (P > 0.01). Error bars indicate 95% confidence interval, ns -not significant.Malaria Journal 2009, 8:242 http://www.malariajournal.com/content/8/1/242
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of IgG antibodies to the antigens over a period of 12
weeks among 42 Kenyan children recovering from an
acute episode of malaria [23]. The majority of responses
peaked one week after the episode and then decayed rap-
idly to very low levels in six to eight weeks (Figure 2).
Although rapid re-infection limited the ability to make
reliable estimates of the half-life of many of the responses,
where estimation was possible, IgG1 and IgG3 responses
had a mean half-life of about ten and six days, respec-
tively, periods that are shorter than those normally
described for the catabolic elimination of these subclasses
of antibody. Furthermore re-infection failed to signifi-
cantly boost the responses [24].
A full discussion on the possible mechanisms underlying
the brevity of anti-malaria antibody is beyond the scope
of this paper. It has been suggested that the brevity is par-
tially attributable to the predilection of the responses
towards short-lived IgG3 [25-28]. However, the study
cited above showed that IgG1 to malaria antigens
responses are also short-lived [23]. Other possible reasons
cited include poor development of malaria antigen-spe-
cific memory and long-lived plasma cells [29-31]. How-
ever, it suffices to say that the mechanisms are still poorly
understood, and none of these mechanisms would
explain a rate of decay more rapid than the catabolic half-
life of the antibody.
Heterogeneity of exposure to malaria
Disease incidence is not homogenously distributed
within an endemic population. Mathematical modelling
of transmission data from different geographic sites by
Woolhouse et al suggested that about 20% of endemic
populations bears 80% of the burden of leishmaniasis,
schistosomiasis, sexually transmitted diseases and malaria
disease [32]. Subsequent modelling of a set of data that
combined malaria measurements from more than 90
communities around Africa showed that indeed, the rela-
tionship between community incidence of disease and
rates of infectious bites was best explained by a model that
incorporated a similar level of heterogeneity in infection
[33,34]. The inferences from these models are supported
by field data from several places. In a one year study mon-
itoring malaria cases among six villages in northern Ethi-
opia, 50% of malaria cases occurred in 18% of the
households under study while in Belize among 200
households monitored over a period of seven years, 8%
the households accounted for 50% of cases detected [35].
GIS based-mapping of distribution of malaria cases in
Kampala, Uganda found that local high transmission clus-
ters with a total of 43 children living in them accounted
for 22% of cases observed over a two year follow up
period despite accounting for only 6.7% of the person-
time of observations for the cohort [36]. Similar clustering
of malaria has been observed among children resident
Antibody responses profiles to two types of MSP2 (red - A type and green - B type) among ten children illustrating the rapid  rate of antibody decay following an acute episode of malaria Figure 2
Antibody responses profiles to two types of MSP2 (red - A type and green - B type) among ten children illus-
trating the rapid rate of antibody decay following an acute episode of malaria. The triangles under the graphs indi-
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within a single area of Kilifi, Kenya. Some of the children
had a discrepancy of two or more between the numbers of
observed and expected episodes of malaria during follow
up. 18% of children fell into this group, more than
expected by chance alone. At the other extreme, there was
a group of children that had neither clinical malaria nor
parasites at six cross-sectional surveys during a four-year
period [37]. Further observations from Daraweesh, an
area of low transmission in Sudan, where over 32 percent
of individuals did not suffer a malaria episode over a
period of 11 years while others suffered up to eight epi-
sodes underlines the variations in individual susceptibil-
ity to malaria episodes [38].
A major reason for this heterogeneity appears to be varia-
tions in local transmission intensity. The commonly used
low resolution malaria endemicity maps often show large
areas as having homogenous intensity of transmission
while in reality relatively high level of heterogeneity in
transmission occur even within very short distances
[39,40]. Through fine resolution mapping using GPS,
proximity to mosquito breeding sites, such as rivers,
dams, vegetation clusters and even temporary pools in
wheel tracks, has been shown to play a major role in deter-
mining local heterogeneity in transmission [35,40-43].
Studies in The Gambia [42] and elsewhere [35] indicated
that transmission intensity falls dramatically a short dis-
tance from breeding sites. Importantly clusters of high
transmission are not necessarily spatially fixed and may
shift over time depending on variations in environmental
factors that affect breeding sites [41,44].
In addition to proximity to breeding site, there may be
host-related factors that contribute to heterogeneity in the
distribution of disease incidence. The finding that in Kilifi
familial relationship (after adjusting for shared house-
hold) may explain up to a third of the variability in
malaria disease experience [45] suggests that in addition
to the known malaria resistance genotypes, such as sickle
cell trait, there may be a large number of unidentified
genes that contribute to variations in individuals' inherent
susceptibility to malaria. Furthermore, modeling of
human-mosquito contact rates suggest that the contact is
not purely random [46], possibly because of inherent var-
iations in host attractiveness to mosquitoes [47]. This
means that even individuals who share the same residence
might nonetheless be at different risks of receiving
infected bites.
Implication of antibody brevity and 
heterogeneity in longitudinal studies of malaria 
immunity
Clearly both brevity of antibody responses and transmis-
sion heterogeneity have important implications for longi-
tudinal malaria immunity studies. Figure 3 illustrates how
these two factors hinder attempts to define an individual's
true malaria immunity status in a longitudinal frame-
work. First, because of these factors, a cross-sectional sur-
vey is inadequate as a window into an individual's malaria
exposure history. As shown in the figure, the two serolog-
ical categories of individuals (antibody negative and pos-
itive) apparent during a cross-sectional survey are not
homogenous groups, yet classical analysis treats them as
such because it is not possible to distinguish the various
subgroups within them. Within the antibody negative
group are individuals that lack antibodies because they
are under very low or no exposure (group 1a). Other indi-
viduals in the same group are those under exposure but
who either did not mount detectable responses to recent
exposure (group 3) or if they did, the responses were weak
have since decayed (group 1b). On the other hand, the
antibody positive group consist of non-immune people
with recently treated (group 2) or current acute infection
to which they are making responses (group 4a) or
immune individuals (group 4b) harbouring chronic
infections that may in turn help maintain the high levels
of responses. Variations in the proportions of these sub-
groups in different endemicity settings might in part be
the explanation for the differences in the strength of asso-
ciation between antibodies and protection reported by
different studies.
Second, even antibody responses that are "protective"
might too brief to protect throughout the follow-up
period (groups 2 and 4a). In such a case the antibodies
would serve only as a makers of exposure. Relative to non-
exposed individuals (group 1), the exposed groups, anti-
body levels notwithstanding, are more likely to eventually
present with a clinical episode of malaria leading to the
paradoxical conclusion seen in a number of studies (Table
1) that antibodies are associated with increased risk of
clinical malaria. Finally, the figure shows that since both
non exposure (group 1) and the genuine immunity
(group 4b) leads to similar outcome, including the unex-
posed group in analysis will undermine assignment of a
protective role to immune responses. This may help
explain why in several recent studies (Table 1), we were
able to assign a protective role for antibodies against vari-
ous malaria antigens only among children who were
asymptomatically infected at the time of the serological
survey. In other words, having the infection at the survey
marked out children that were under some level of expo-
sure and in whom therefore lack of clinical disease during
the follow-up most likely reflected immunity.
Dealing with heterogeneity in exposure and 
brevity of responses in longitudinal studies
The discussion above indicates the need for study designs
and analysis approaches that can circumvent the problem
of heterogeneous exposure and unstable measures of theMalaria Journal 2009, 8:242 http://www.malariajournal.com/content/8/1/242
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responses. One way of correcting for differences in expo-
sure is to use levels of antibodies to total schizonts extract
as a proxy of exposure. This approach assumes a linear
relationship between exposure and antibody levels. How-
ever, this may not be the case partly because of antibody
saturation after repeated exposure, seasonal variation, and
variations in individual's inherent capacity to respond to
malaria antigens. In addition, if measured at the begin-
ning of follow-up, antibodies against schizonts extract
reflect past exposure, but not necessarily exposure during
the follow-up. Repeated measurement during the follow-
up period could help circumvent this problem and give a
better picture of the exposure the child faced during this
period.
While the incidence of clinical malaria among endemic
populations falls with age, the prevalence of parasitiza-
tion typically rises to a plateau, which is maintained to
early adulthood, and even among older adults a substan-
tial proportion is asymptomatically infected at any given
time. This suggests that the immunity to malaria acquired
with age, while down regulating the severity of infections,
does not mediate complete resistance to infection. As
such, the ability to harbour an infection asymptomatically
rather than having no infection at all might be a more rea-
sonable proxy for immunity in longitudinal studies. The
corollary to this being that in endemic areas, individuals
who fail to get re-infected within a given period after rad-
ical malaria treatment may be more likely to be unex-
posed rather than immune to re-infection. Therefore
carrying out radical treatment prior to follow-up and then
doing cross-sectional parasitological surveys within three
months to six months of the treatment might be a good
way of distinguishing between truly immune individuals
The influence of exposure history on an individual's apparent serological and parasitological status at a cross-sectional survey  (CS) and the individual's clinical history subsequent to the CS Figure 3
The influence of exposure history on an individual's apparent serological and parasitological status at a cross-
sectional survey (CS) and the individual's clinical history subsequent to the CS. Ab +ve/-ve = antibody positive or 
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and those who are simply unexposed. Those found at the
survey to have asymptomatic infection but did not suffer
a clinical episode during follow-up can be considered to
be immune while those who suffered a febrile episode
during the follow-up are considered susceptible. Individ-
uals who have no parasites at the second survey and who
did not present with an episode during follow-up should
be considered potentially unexposed and left out of anal-
ysis. Indeed, in a longitudinal study in Kilifi, which fol-
lowed this approach the effects of age, anti-VSA antibody
responses and transmission intensity were most evident
when children who remained uninfected during follow-
up (i.e. neither asymptomatic nor febrile infection) in the
analysis were excluded in the analysis [48].
An assumption in this approach is that most asympto-
matic infections last for several months rather than days.
In other words, only in a small proportion of the popula-
tion will asymptomatic infections during follow-up be so
brief as to terminate before the cross sectional survey and
therefore cause those individuals to be erroneously con-
sidered as unexposed and excluded from analysis along
with those who were genuinely unexposed. Observation
from malariotherapy work, where non-immune individu-
als were deliberately infected with malaria parasites, sug-
gest that untreated infections can last for up to nine
months with an average of over three months [49].
While very closely space serological surveys would be the
ideal way of dealing with the difficulty raised by brevity of
potentially "protective" antibody responses, both logistic
and ethical constrains makes it difficult carry out too
closely spaced surveys. Based on the observed decay pro-
files of anti-malarial antibodies [23], a serological survey
six weeks after the initial bleed (and half way through the
follow-up period) would be sufficient for more accurate
Table 1: The influence of parasitological status on the association between the risk of clinical episode of malaria and antibodies against 
various malaria antigens
Study population [ref] Antigen Parasites alone Antibodies alone Parasites + Antibodies
Chonyi [50] AMA1 Pro/DI/II/III 2.65 (P < 0.050) 1.87 (P = 0.093) 0.38 (P < 0.050)
Chonyi [50] AMA1 DI/II/III 2.12 (P = 0.049) 0.049 (P < 0.050)
Chonyi [7] MSP2 type A 2.95 (P < 0.050) 8.94 (P = 0.008) 0.47 (P = 0.414)
Chonyi[7] MSP2 type B 3.97 (P < 0.050) 0.76 (P = 0.599) 0.83 (P = 0.818)
chonyi [51] MSP3 1.14 (P = 0.717) 0.41 (P = 0.011)
Ngerenya[52] VSA (isolate A4U) 3.78 (P = 0.022) 1.35 (P= 0.567) 1.67 (P = 0.325)
VSA (isolate A4 40C) 5.35 (P = 0.005) 2.88 (P = 0.064) 1.55 (P = 0.402)
VSA (isolate 3D7) 7.10 (P = 0.004) 2.01 (P = 1.700) 1.43 (P= 0.479)
VSA (isolate P1) 2.53 (P = 0.035) 3.72 (P = 0.050) 1.38 (P = 0.587)
Antibody responses stratified by titre
Variant surface antigens
Ngerenya [18] Medium tertile 5.90 (P = 0.018) 2.05 (P = 0.06) 0.21 (P = 0.200)
Highest tertile 4.34 (P = 0.01) 0.09 (P = 0.041)
MSP2 type A
Chonyi [7] Lowest quartile 2.95 (P < 0.050) 4.27 (P = 0.050)
Highest quartile 0.56 (P = 0.418)
Ngerenya [7] Lowest quartile 1.66 (P < 0.050) 1.11 (P = 0.740)
Highest quartile 0.39 (P = 0.044)
MSP2 type b
Chonyi [7] Lowest quartile 3.97 (P < 0.050) 1.31 (P = 0.530)
Highest quartile 0.19 (P = 0.013)
Ngerenya [7] Lowest quartile 1.58 (P < 0.050) 1.37 (P = 0.547)
Highest quartile 0.78 (P = 0.560)
Age adjusted risk of suffering a clinical episode of malaria among children in two areas of Kilifi, Kenya (Ngerenya - low transmission and Chonyi- 
moderate transmission) during follow-up depending on their anti-malarial antibody serological and malaria parasitological status at pre-follow-up 
cross-section survey. Significant associations (P < 0.05) are highlighted in bold. AMA 1 (Pro/DI, II, III) -Apical Membrane Antigen 1 prodomain and 
domains 1, 2, and 3. MSP2/3- Merozoite Surface Protein 2/3, VSA - Variant Surface Antigen.Malaria Journal 2009, 8:242 http://www.malariajournal.com/content/8/1/242
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monitoring of an individuals serological status during fol-
low-up and placing the measurement closer to any epi-
sode of clinical malaria they may have.
Conclusion
Conflicting results concerning the protective efficacy of
antibodies against putative vaccine candidate antigens
makes it difficult to interpret their relevance to under-
standing immunity to malaria. In this paper, two factors
that might undermine the ability to detect protective anti-
body responses to malaria antigens in a classical longitu-
dinal studies framework namely the brevity of antibody
responses to malaria and heterogeneity in exposure have
been discussed. A modification of the framework to
include repeated closely spaced surveys to account for
antibody decay and radical treatment before the start of
follow-up in order to distinguish between genuinely
immune individuals and those who are simply unexposed
is proposed.
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